Alnylam and Sanofi Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. CBRS
2. FDX
3. KBH
4. HON
5. HTZ
6. MRK
7. TTWO
8. USO
9. QCOM
10. INFY

Go back to Alnylam and Sanofi Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy

Alnylam Pharmaceuticals (ALNY) PT Raised to $128 at JMP Securities

September 20, 2017 2:14 PM EDT

JMP Securities analyst Michael King raised his price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $128.00 (from $101.00) while maintaining a Market Outperform rating after the company announced positive top-line results for the Phase III APOLLO trial.

"We believe patisirans success in APOLLO... More

Alnylam Pharma (ALNY) Adds to Gains; Shares up 40%

September 20, 2017 10:23 AM EDT

Alnylam Pharma (NASDAQ: ALNY) pushes to highs following earlier positive data. Shares are now p 39.6%.

... More

Alnylam Pharma (ALNY) to Resume Trading at 7:30 AM ET

September 20, 2017 7:06 AM EDT

Alnylam Pharma (NASDAQ: ALNY) to Resume Trading at 7:30 AM ET

... More